21st Meeting of the European Hematology Association (EHA) – Virtual Symposium
At Thermo Fisher Scientific, we have developed advanced next-generation sequencing (NGS) solutions to address key challenges in the molecular analysis of hematologic malignancies. Our automated NGS platforms, like the Ion Torrent Genexus System, provide simple workflows and deliver results in as fast as 1–2 days.
View our EHA 2022 virtual symposium on-demand to learn how your peers have implemented in-house NGS to simplify the path to answers in the study of myeloid and lymphoid cancers.
Speed and simplicity: Molecular profiling of myeloid malignancies using next-generation sequencing
Marianne Grantham
Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust, UK
The impact of fast NGS molecular profiling in myeloid malignancy research
Dr. Dolores Colomer
Head of Hematopathology, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
Adopting rapid NGS for the study of haemato-oncology malignancies
Dr. Lihui Wang
Molecular Lead, HODS, Cheshire & Merseyside Cancer Network, Liverpool, UK
Dr. Geetha Menon
Clinical Director, HODS, Cheshire & Merseyside Cancer Network, Liverpool, UK
Please fill out the form below to register for this virtual symposium.